Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals

Farah M. Shurrab 1, Nadin Younes 1,2, Duaa W. Al-Sadeq 1,3, Na Liu 4, Hamda Qotba 5, Laith J. Abu-Raddad 6,7,8, Gheyath K. Nasrallah 1,2,*

1 Biomedical Research Center, Qatar University, 2713, Doha, Qatar
2 Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, 2713, Doha, Qatar
3 College of Medicine, Member of QU Health, Qatar University, 2713, Doha, Qatar
4 Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China
5 Department of Clinical Health Care Centers, 26555, Doha, Qatar
6 Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation—Education City, 24144, Doha, Qatar
7 World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation—Education City, 24144, Doha, Qatar
8 Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, NY, 10065, USA

A R T I C L E   I N F O

Article history:
Received 5 January 2022
Revised 19 February 2022
Accepted 23 February 2022

Keywords:
SARS-CoV-2
COVID-19
Serology
Lateral Flow Assay
Fluorescence immunoassay

A B S T R A C T

Background: A vast majority of the commercially available lateral flow immunoassay (LFIA) is used to detect SARS-CoV-2 antibodies qualitatively. Recently, a novel fluorescence-based lateral flow immunoassay (LFIA) test was developed for quantitative measurement of the total binding antibody units (BAUs) (BAU/mL) against SARS-CoV-2 spike protein receptor-binding domain (S-RBD).

Aim: This study aimed to evaluate the performance of the fluorescence LFIA Fincare™ 2019-nCoV S-RBD test along with its reader (Model No.: FS-113).

Methods: Plasma from 150 reverse transcriptase–PCR (RT-PCR)-confirmed positive individuals and 100 pre-pandemic samples were tested by Fincare™ to access sensitivity and specificity. For qualitative and quantitative validation of the FinCare™ measurements, BAU/mL results of FinCare™ were compared with results of 2 reference assays: the surrogate virus-neutralizing test (sVNT, GenScript Biotech, USA) and the VIDAS®3 automated assay (BioMérieux, France).

Results: Fincare™ showed 92% sensitivity and 100% specificity compared with PCR. Cohen’s Kappa statistic denoted moderate and excellent agreement with sVNT and VIDAS®3, with values being 0.557 (95% CI: 0.32–0.78) and 0.731 (95% CI: 0.51–0.95), respectively. A strong correlation was observed between Fincare™/sVNT (r = 0.7, p < 0.0001) and Fincare™/VIDAS®3 (r = 0.8, p < 0.0001).

Conclusion: Fincare™ is a reliable assay and can be used as a surrogate to assess binding and neutralizing antibody response after infection or vaccination, particularly in none or small laboratory settings.

© 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

1. Introduction

Soon after the emergence of SARS-CoV-2 in December 2019 and its declaration as a pandemic by the World Health Organization (WHO), the need for accurate, sensitive, and rapid detection of SARS-CoV-2 for the control and prevention of the disease was urgent (Theel et al., 2020). Several commercial COVID-19 test kits were developed in response to this urgent need for the detection of either nucleic acid or antibodies (Van Walle et al., 2021). Although reverse transcriptase–PCR (RT-PCR) is used as a gold standard test, it requires specialized conditions, expensive equipment, and qualified personnel for sampling and testing. These limitations pose a challenge in a pandemic setting, which requires rapid and reliable tests that can be used to screen populations (Dortet et al., 2021). Thus, serological testing, particularly point-of-
care approaches such as lateral flow immunoaassay (LFIA), provides a rapid, portable, and cost effective method that is complementary to RT-PCR. In addition, serological tests have important applications in public health; they can be used in epidemiological survey studies, detect past infections, and determine herd immunity in the community. Furthermore, serological tests have a vital role in convalescent plasma treatment and determining vaccine effectiveness (Nadoushan et al., 2020).

Conventional LFIA used in clinical settings for diagnosing SARS-CoV-2 infection are done manually within 15 minutes, and the results are interpreted qualitatively by the naked eye. As a result, errors due to manual operation and inadequate visual sensitivity interpretation can occur. Recently, Wondfo Biotech developed fluorescence-based lateral flow immunoaassay (LFIA) to detect total anti-S-RBD binding antibodies (binding antibody unit [BAU]) against SARS-CoV-2. Finecare™ 2019-nCoV RBD Antibody Test is a fluorescence immunoaassay that is carried out semiautomatically along with a small portable device. The combination of fluorescence and LFIA provides higher sensitivity, allows quantitative detection of antibodies, and is easily affordable and accessible in small clinical laboratories, research settings, or point-of-care testing after infection or vaccination.

To the best of our knowledge, there is only 1 report in the literature evaluating the rapid fluorescence-based LFIA immunoassays, which aimed to validate the performance of rapid SARS-CoV-2 IgM and IgG test kits based on fluorescence immunochromatography (Kang et al., 2021). In this study, we aimed to evaluate the performance of a rapid semiautomated fluorescence-based LFIA. This assay is designated to provide qualitative and quantitative measurements of SARS-CoV-2 anti-S-RBD total antibodies. One of the biggest advantages of this assay over the commercially available LFIA is that not only are the results quantitative but they are also converted to BAU/mL (instead of AU/mL) as recently recommended by WHO.

2. Materials and Methods

2.1. Study design and ethical approval

We evaluated the performance of Finecare™ 2019-nCoV Antibody test and its reader (Model No.: FS-113) (Guangzhou Wondfo Biotech Co., China) (from here on abbreviated as Finecare™). The serum samples were collected from volunteer individuals between July 26 and September 9, 2020 as a nationwide survey study in Qatar (Al-Thani et al., 2020, Syed et al., 2021). The clinical symptoms of the samples varied between asymptomatic and symptomatic cases (S1 table). The project was approved by the institutional review board of Qatar University (QU-IRB 1492-E/21 and QU-IRB 1469-E/21). These samples were used in previous studies (Al-Jghfeee et al., 2021, Yassine et al., 2021, Younes et al., 2021).

2.2. Sensitivity and specificity determination

The sensitivity of Finecare™ was determined using sera from 150 RT-PCR–confirmed individuals (7–21 days). Qiagen extraction kit was used to extract RNA from nasopharyngeal swab specimens. Then, the SuperscriptIII One-Step RT-PCR kit was used to test for SARS-CoV-2 according to manufacturer’s instruction (Cat No. 12594100, ThermoFisher, USA) (Yassine et al., 2021). Samples were tested using 2 sets of primers targeting the E gene and confirmed with 2 different sets of primers targeting the RdRp gene (Corman et al., 2020, Yassine et al., 2021). Complete descriptions for these participants are summarized in Table S1. The specificity was examined using 100 pre-pandemic plasma samples collected before 2019, which were used in previous studies (Nasrallah et al., 2018, Nasrallah et al., 2019, Smatti et al., 2020). The panel included plasma samples seropositive for (a) dengue virus (n = 26), (b) parvovirus B19 (n = 8), and (c) nonrespiratory viruses (n = 66).

2.3. Serological assays

2.3.1. Finecare™ 2019-nCoV RBD Antibody Test

Finecare™ 2019-nCoV RBD Antibody Test is a fluorescence immunoaassay technology, specifically the sandwich immunodetection method. It uses fluorescently labeled SARS-CoV-2 S-RBD proteins to form immune complexes by binding to SARS-CoV-2 S-RBD antibodies present in the specimen. It is used along with the Finecare™ FIA Meters (Model No.: FS-113) for the quantitative detection of total antibodies against SARS-CoV-2 S-RBD (Co.). The test can be done using various specimens, including finger-stick whole blood, venipuncture blood, serum, or plasma. There are 2 test modes for Finecare™ FIA Meters: standard test mode and quick test mode. The difference is that samples are incubated inside the cartridge holder of Finecare™ FIA Meters in the standard mode, whereas the samples are incubated at room temperature in the quick mode. The test was done according to the manufacturer’s instructions. In brief, 20 μL of plasma was added to the provided buffer tube and mixed for 45 seconds. Then, 75 μL was added to the test cartridge, incubated for 15 minutes at room temperature (RT), and then inserted in the test cartridge holder of Finecare™ FIA Meters holder for measurement on quick mode. Finecare™ FIA Meter displays the test result automatically on the screen. The results are given as relative fluorescence units (RFU, arbitrary units [AU/mL]). This test has a WHO international standardization factor to convert readings to AU/mL to binding antibody units (BAU/mL) (1 AU/mL = 20 BAU/mL). Readings ≥1 AU/mL or ≥20 BAU/mL indicate positive results.

2.3.2. cpPass GeneScript sVNT

Food and Drug Administration (FDA)-approved SARS-CoV-2 surrogate virus neutralization test (sVNT) developed by GeneScript is widely used in the literature as a reference assay to measure neutralizing antibodies (Cat. No. L00847-C, GenScript Biotech, USA) (Ismail et al., 2021, Meyer et al., 2020, Younes et al., 2021). This assay detects antibodies that inhibit the interaction between SARS-CoV-2 S-RBD–horseradish peroxidase (HRP) fusion protein and ACE2 that is coated in a 96-well plate (Meyer et al., 2020). The assay highly correlates with conventional pseudovirus neutralization tests (pVNTs, R2 = 0.84) and showed high specificity (99.9%) and sensitivity (100%) (Tan et al., 2020). The test was done according to the manufacturer’s instructions. An inhibition value of ≥30% signal inhibition was considered positive and <30% signal inhibition was considered negative. The WHO international standardization factor for this assay was used to convert readings from percent inhibition to IU/mL by applying the recently published formula (Zhu et al., 2021).

2.3.3. BioMérieux VIDAS®3

VIDAS®3 SARS-CoV-2 IgG (REF 424114, BioMérieux, France) is a widely used automated CE-marked in vitro diagnostic (IVD) assay, which was granted the emergency use authorization (EUA) by FDA in early 2021. The assay principle is based on a 2-step enzyme immunoassay combined with an enzyme-linked fluorescent assay (ELFA) detection technique. The test uses a solid-phase receptacle (SPR) coated with SARS-CoV-2 S-RBD of the spike protein. The test was done according to the manufacturer’s instructions. In brief, the test was calibrated with standard (S1), a positive control (C1), and a negative control (C2). Then, 100 μL of the sample was added to the test strip. The results are generated as relative fluorescence value (RFV) and automatically calculated by the instrument; according to the S1 standard and sample RFV, an index value (i) is obtained (where i = RFVsample/RFV S1). The test is
interpreted as negative when \( i < 1.00 \) and positive when \( i \geq 1.00 \) (Renard et al., 2021). All readings were standardized to BAU/mL by applying the WHO international standard (20.33 BAU/mL) for the VIDAS®3 SARS-CoV-2 IgG.

2.4. Statistical analysis

Using RT-PCR as the reference test, sensitivity, specificity, overall percent agreement, and Cohen’s kappa coefficient \( \kappa \) were calculated to assess the performance of Finecare™. \( \kappa \) measures inter-rater reliability as well as the likelihood that an agreement will occur by chance (Ben-David, 2008, McHugh, 2012). \( \kappa \leq 0 \) indicates no agreement, \( \kappa = 0.01–0.20 \) indicates poor agreement, \( \kappa = 0.21–0.40 \) indicates fair agreement, \( \kappa = 0.41–0.60 \) indicates moderate agreement, \( \kappa = 0.61–0.80 \) indicates substantial agreement, and \( \kappa = 0.81–1.00 \) indicates almost perfect agreement (McHugh, 2012). Concordance analysis between Finecare™ and sVNT and VIDAS®3 were conducted. The concordance measures included overall, positive, and negative percent agreement and Cohen’s kappa statistic. The correlation between Finecare™ and each immunoassay was examined using Pearson’s correlation coefficients \( r \) with 95% CI. A coefficient of 0.19 suggests very weak correlation, 0.2–0.39 suggests weak correlation, 0.4–0.59 suggests moderate correlation, 0.6–0.79 suggests strong correlation, and 0.8–1 suggests very strong correlation (Swinscow and Campbell, 2002). Receiving operating characteristic (ROC) curve and Youden’s index \( J \) were used to assess the assay threshold (cutoff indexes), identify optimized ones, and measure the area under the curve \( \text{AUC} \). The relation between AUC and diagnostic accuracy is direct. The larger the AUC the more accurate a test can be considered in its overall performance. Statistically, an AUC of <0.5 suggests no discrimination, 0.7–0.8 is considered acceptable, 0.8–0.9 is considered excellent, and >0.9 is considered outstanding. To determine the optimal threshold for optimal sensitivity and specificity for Finecare™, \( J \) was calculated using the following formula: \[ J = \text{max (specificity + sensitivity)} - 1 \] (Fluss et al., 2005, Unal and medicine, 2017). All statistical analyses were performed using GraphPad Prism version 9.3.0.

3. Results

3.1. Diagnostic Performance of Finecare™ using RT-PCR as a reference test

The overall diagnostic performance of Finecare analyzer compared with RT-PCR is summarized in Table 1. The sensitivity and specificity of Finecare™ were 92% (95% CI: 86.44%–95.80%) and 100% (95% CI: 96.38%–100.00%), respectively. The overall percent agreement with RT-PCR was 96.4% (95% CI: 93.2%–98.1%). Cohen’s Kappa statistic with RT-PCR denoted an excellent agreement with \( \kappa \) coefficient of 0.881 (95% CI: 0.816–0.946).

### Table 1

| Immunoassay | Finecare™ |
|-------------|-----------|
| Sensitivity, % (95% CI) | 92% (95% CI: 86.44%–95.80%) |
| Specificity, % (95% CI) | 100% (95% CI: 96.38%–100.00%) |
| Overall agreement, % (95% CI) | 96.4% (95% CI: 93.2%–98.1%) |
| Cohen’s kappa coefficient, \( \kappa \) (95% CI) | 0.881 (95% CI: 0.816–0.946) |
| ROC curves optimized cutoff index | - |
| Sensitivity using optimized cutoff indexes, % (95% CI) | 94.67% (95% CI: 89.83%–97.27%) |
| Specificity using optimized cutoff indexes, % (95% CI) | 100% (95% CI: 96.34%–100%) |

Abbreviations: ROC, receiver operating characteristic; RT-PCR, reverse transcriptase PCR; S-RBD, SARS-CoV-2 spike protein receptor-binding domain.

3.2. Concordance assessment between Finecare™ test, sVNT, and VIDAS®3

The tests’ concordance assessment is summarized in Table 2. The overall percent agreement for sVNT and VIDAS®3 was 92% (95% CI: 86.5–95.4) and 94.4% (95% CI: 87.6–97.6), respectively. The positive percent agreement ranged from 95.1% (88.0–98.1) for Finecare versus VIDAS®3 to 97.7% (93.5–99.2) for Finecare™ versus sVNT. The negative percent agreement ranged from 50% (95% CI: 29–71.0) for Finecare™ versus sVNT to 88.9% (95% CI: 56.5–98.0) for Finecare™ versus VIDAS®3. Cohen’s Kappa statistic denoted moderate to excellent agreement and ranged between 0.557 (95% CI: 0.32–0.78) for Finecare™/sVNT test combination and 0.731 (95% CI: 0.51–0.95) for Finecare™/VIDAS®3 test combination. Correlation analysis of the readings obtained from Finecare™, sVNT, and VIDAS®3 is illustrated in Figure 1. Both immunoassays showed strong correlation with Finecare™ Pearson’s correlation coefficients \( r \) ranged from 0.70 for Finecare™/sVNT to 0.8 for Finecare™/VIDAS®3.

3.3. Receiver Operating Characteristic (ROC) Curve Analysis

ROC curve analyses showed excellent performance for Finecare™ with an AUC of 0.9627 and \( p < 0.0001 \) (Figure 2). The optimized cutoff for detecting total antibodies against RBD was derived on the basis the ROC curves and the calculated \( J \). The cutoff obtained was >10.70 compared with the manufacturer’s cutoff >20. Applying this new cutoff showed improved sensitivity, from 92% to 94.67%, whereas the specificity remained 100% (Table 1).

4. Discussion

This study validated the performance of Finecare™ 2019-nCoV RBD fluorescence immunoassay for detecting total antibodies against SARS-CoV2 S-RBD after infection. A panel of 150 samples collected from RT-PCR–confirmed individuals and 100 prepanemic sera were used to evaluate the assays’ performance. To our knowledge, this is the first study conducted to validate the fluorescence-LFIA-based Finecare 2019-nCoV RBD Antibody test, which marks the novelty of this research work.

Finecare test showed high sensitivity and specificity comparable to sVNT and VIDAS®3 and other immunoassays in the market. VIDAS®3 was reported to have a sensitivity and specificity of 88.3% and 98.4%, respectively (Younes et al., 2021). Similarly, sVNT reported a high specificity (99.9%) and sensitivity (95%–100%) (Tan et al., 2020). It is noteworthy that our cohort samples were collected from Qatar community volunteers; thus, the cases varied between symptomatic and asymptomatic. It was noticed that of the 12 negative samples by Finecare, 8 were asymptomatic. Earlier studies reported that severity of the case affects humoral
response in patients (Wu et al., 2021, Zhao et al., 2020). Previously, we reported that the sensitivity of immunoassay was higher in symptomatic patients than in the asymptomatic patient group (Younes et al., 2021). In addition, the sensitivity of Fincare assay for estimating anti-S-RBD or neutralizing antibodies could be overestimated because the S-RBD antigen in this assay is designed to detect antibodies specific to the wild-type (Wuhan) but not to other SARS-CoV-2 variants. Some of these variants, such as Omicron, accumulate significant numbers of mutations in the S-RBD domain. These mutations might decrease the affinity of binding and neutralizing antibodies to S-RBD, which in turn affect the sensitivity of the assay.

We evaluated the degree of correlation between Fincare™ with sVNT and VIDAS®3. A strong correlation was obtained between Fincare™ and both assays (Figure 1); however, VIDAS®3 showed a slightly higher correlation. This is because both VIDAS®3 and Fincare™ detection methods are based on enzyme-linked fluorescent and target antibodies against the S-RBD domain. This is particularly important; the Fincare™ rapid antibody test could detect neutralizing antibodies and serve as a surrogate for the advanced automated immunoassays in clinical settings to measure the humoral immune response after vaccination or infection and research context. ROC curve analysis was also performed to determine the optimal cutoff indexes for Fincare (Figure 2). The new cutoff value showed improved sensitivity without affecting the specificity. However, the cutoff values could be adjusted depending on the clinical setting or research context. For instance, in high-prevalence settings, higher thresholds may be desirable for screening purposes, whereas lower cutoff may be helpful for diagnosis purposes (Ismail et al., 2021).

Our study had some limitations; most of our RT-PCR samples were collected from asymptomatic individuals (Table S1), which might have underestimated the assay’s sensitivity. In addition, the control group did not include samples for other coronaviruses or influenza that might cross-react with SARS-CoV-2, which could have led to an overestimated specificity.

In conclusion, depending on characteristics of emerging variants, our data showed that Fincare 2019-RBD antibody test showed excellent performance in terms of sensitivity, specificity, and overall agreement, with RT-PCR as a reference test. In addition, in terms of correlation with the FDA-approved sVNT from GenScript and the automated analyzer VIDAS®3 from bioMérieux, Fincare™ immunoassay showed an outstanding performance in detecting total antibodies in serum samples against SARS-CoV-2. Thus, this assay could be reliable for the quantitative detection of antibodies in the vaccinated population and recovered patients.

**Conflict of interest**

GKN would like to declare that all test kits used in this study were provided as in-kind support for his laboratory to test sero-prevalence of anti-SARS-CoV-2 and antibody response among vaccinated and infected individuals in Qatar.

**Funding**

This work was made possible by grant number UREP28-173-3-057 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors.
Acknowledgment

We would like to thank Qatar National Research Fund (a member of Qatar Foundation) for funding this work.

Author contributions

Conceptualization: GKN, NL. Participant recruitment and demographic data collection: HQ. Laboratory testing: FMS, DWA, NY. Supervision: GKN. Data analysis: GKN, FMS, NY, NL. First draft writing: GKN, FMS, NL. Review and editing: IJA, GKN. Funding: GKN, IJA.

Ethical statement

The study was conducted according to the guidelines of the Declaration of Helsinki and was reviewed and approved by the institutional review board of Qatar University (QU-IRB 1492-E/21 and QU-IRB 1469-E/21). Informed consent was obtained from all subjects involved in the study before collecting samples.

Data availability

All data produced in this study are available upon reasonable request to the authors.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ijid.2022.02.052.

References

Al-jigheefee HT, Yassine HM, Nasrallah GJKJP. Evaluation of antibody response in symptomatic and asymptomatic COVID-19 patients and diagnostic assessment of new IgM/IgG ELISA kits. Pathogens 2021;10(2):161.
Al-Thani MH, Farag E, Bertollini R, Al Romaihi HE, Abdeen S, Abdellkarim A, et al. Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar. medRxiv 2020. doi:10.1101/2020.11.24.20237719.
Ben-David AJEJSWA. Comparison of classification accuracy using Cohen's Weighted Kappa. Expert Systems with Applications 2008;34(2):825–32.
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-ncov) by real-time RT-PCR. Eurosurveillance 2020;25(3).
Dortet L, Ronat J-B, Vauloup-Fellous C, Langendorf C, Mendels D-A, Emeraud C, et al. Evaluating 10 commercially available SARS-CoV-2 rapid serological tests by use of the STARD (Standards for Reporting of Diagnostic Accuracy Studies) method. Journal of clinical microbiology 2021;59(2):e02342 -20.
Fluss R, Faraggi D, BJJMBlMM Reiser. Estimation of the Youden Index and its associated cutoff point. Journal of Mathematical Methods in Biosciences 2005;47(4):438–72.
Ismail A, Shurrab FM, HT Al-jigheefee, Al-Sadeq DW, Qotba H, Al-Shaar IA, et al. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays. Front Biosci. (Landmark Ed) 2021;26(7):198–206 Jul 30 PMID: 34340267. doi:10.25256/4934.
Kang K, Huang L, Ouyang C, Du J, Yang B, Chi Y, et al. Development, performance evaluation, and clinical application of a Rapid SARS-CoV-2 IgM and IgG Test Kit based on automated fluorescence immunoassay. Journal of Medical Virology 2021;93(5):2838–47.
McHugh MLJBlM. Interrater reliability: the kappa statistic. Biochimica medica 2012;22(3):276–83.
Meyer B, Reinmerk J, Torrinci G, Brouwer F, Godere G-J, Verly S, et al. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerging microbes & infections 2020;9(1):2394–403.
Nadoussan MJ, Ahmadi A, Ghotbi MJ, FajjoP. Serology testing for SARS-CoV-2: Benefits and challenges. Iranian Journal of Pathology 2020;15(3):154.
Nasrallah GK, Dargham SR, Mohammed L, Abu-Raddad LJJMmmv. Estimating seroprevalence of herpes simplex virus type 1 among different Middle East and North African male populations residing in Qatar. Journal of medical virology 2018;90(1):184–90.
Nasrallah GK, Dargham SR, Sahara AS, Elsidiq MS, Abu-Raddad LJJMpvC. Performance of four diagnostic assays for detecting herpes simplex virus type 2 antibodies in the Middle East and North Africa. Journal of Clinical Virology 2019;111:33–8.
Renard N, Daniel S, Cayet N, Pecquet M, Raymond F, Pons S, et al. Performance Characteristics of the Vidas SARS-CoV-2 IgM and IgG Serological Assays. Journal of clinical microbiology 2021;59(4):e02292 --20.

Table 2

| Comparison | Overall Percent Agreement(95% CI) | Cohen's Kappa Coefficient (95% CI) |
|------------|----------------------------------|-----------------------------------|
| **VNT**    | **VIDAS®3**                      |                                   |
| Positive   | 92.0%(86.5–95.4)                 | 0.558(0.32–0.78)                  |
| Negative   | 97.7%(93.5–98.8)                 | 0.731(0.51–0.95)                  |

Abbreviations: sVNT, surrogate virus-neutralizing test.
Smatti MK, Nasrallah GK, Al Thani AA, Yassine HMJV. Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent cellular cytotoxicity (ADCC) in human sera using novel stabilized stem nanoparticle probes. Vaccine 2020;38(4):815–21.

Swinscow TDV, Campbell MJ. Statistics at square one: Bmj London, 2002.

Syed MA, Al Nuaimi AS, Nasrallah GK, Althani AA, Yassine HM, Zainel AA, et al. Epidemiology of SARS-CoV2 in Qatar’s primary care population aged 10 years and above. BMC infectious diseases 2021;21(1):1–11.

Tan CW, Chia WN, Qin X, Liu P, Chen Mi-C, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nature biotechnology 2020;38(9):1073–8.

Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Klijnern Kadihoda. The role of antibody testing for SARS-CoV-2: is there one? Journal of clinical microbiology 2020;58(8):e00797–20.

Usal IF, medicine mni. Defining an optimal cut-point value in ROC analysis: an alternative approach. Computational and mathematical methods in medicine. 2017.

Van Walle I, Leitmeyer K, Broberg EKJE. Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020. MedRxiv 2021;20(45).

Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nature communications 2021;12(1):1–9.

Yassine HM, Al-Jighefee H, Al-Sadeq DW, Dargham SR, Younes SN, Shurrab F, et al. Performance evaluation of five ELISA kits for detecting anti-SARS-CoV-2 IgG antibodies. International Journal of Infectious Diseases 2021;102:181–187.

Younes S, Al-jighefee H, Shurrab F, Al-Sadeq DW, Younes N, Dargham SR, et al. Diagnostic efficiency of three fully automated serology assays and their correlation with a novel surrogate virus neutralization test in symptomatic and asymptomatic SARS-CoV-2 individuals. Microorganisms 2021;9(2): 245.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clinical infectious diseases 2020;71(16):2027–34.

Zhu F, Althaus T, Tan CW, Costantini A, Chia WN, Chau NVV, et al. WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. The Lancet Microbe 2021.